Table 3.
Objective response | 100 mg | 150 mg | 200 mg | Total |
---|---|---|---|---|
(n = 3) | (n = 3) | (n = 13) | (n = 19) | |
CR | 0 | 0 | 0 | 0 |
PR | 1 (33%) | 0 | 5 (39%) | 6 (32%) |
SD | 2 (67%) | 3 (100%) | 8 (62) | 13 (68) |
PD | 0 | 0 | 0 | 0 |
ORR (95%CI) | 33% (1−91%) | 0 (0–71%) | 39% (14−68%) | 32% (13−57%) |
DCR (95%CI) | 100% (29−100%) | 100% (29−100%) | 100.0 (75−100%) | 100.0 (82−100%) |
PFS (month, 95%CI) | 4.6 (3.7-NA) | 5.5 (2.6–13.0) | 5.7 (4.8–16.7) | 5.6 (4.6–13) |